← All trials
NCT02584816
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2015
- Primary completion
- Jan 1, 2017
- Completion date
- Apr 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Serum Institute of India Pvt. Ltd.Lead sponsor
- Serum Institute of India Pvt. Ltd.Study director
- PATHCollaborator
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant)
- dipropyltryptamine
- brv-pv
- bivalent oral polio vaccine (bopv), type 1 and type 3
- bivalent oral polio vaccine (bopv), type 1 and type 3
- human rotavirus, live attenuated
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.